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PERSPECTIVES IN CLINICAL NEPHROLOGY
Primary renal abnormalities in hereditary hypertension
There is a well documented connection between hypertension
and salt intake which has been demonstrated in the normal dog [1,
2], rabbit [3], rat [4—6], baboon [7], chimpanzee [8] and human
[9]. There is, in addition, a profusely documented connection
between hypertension and acquired renal disease, or experimental
surgical manipulations of the kidney, in which the rise in blood
pressure is in a large part due to the kidney's impaired ability to
excrete sodium. In humans there are two clear cut examples where
an isolated impairment in the kidney's ability to excrete a normal
sodium intake causes hypertension: Liddle's syndrome and the
syndrome of apparent mineralocorticoid excess (AME) [10—12].
In both, a single genetic disturbance in the distal tubule acceler-
ates sodium reabsorption. In one patient with Liddle's syndrome
the primacy of the kidney in causing the blood pressure to rise was
confirmed by renal transplantation. Following bilateral nephrec-
tomy and substitution of a kidney from a normal donor the blood
pressure became normal [13].
In hypertensive strains of rats and essential hypertension it is
likely that the rise in arterial pressure is also due to an abnormal-
ity of the kidney. In the hypertensive rats this conclusion stems
from renal cross transplantation experiments between a hyperten-
sive and a normotensive strain rat [14—21]. Similarly, the high
blood pressure of patients with essential hypertension and termi-
nal nephrosclerosis became normal (over a mean follow-up period
of 4.5 years) when, following bilateral nephrectomy, they were
transplanted with a kidney from a young normotensive donor [22].
Though in the hypertensive strains of rat there is ample evidence
that the rise in pressure is related to an impaired ability to excrete
sodium [23—25], the evidence is less direct in essential hyperten-
sion [26]. Compared to control subjects, volume expansion with
saline in normotensive first degree relatives of patients with
essential hypertension leads to a rise in blood pressure and
reduced sodium excretion, suggesting an abnormal pressure-
natriuresis relationship [27—30]. Very rapid volume expansion in
normotensive children of hypertensive parents however, leads to
accelerated natriuresis [31], a phenomenon also seen in estab-
lished hypertension [32]. A prolonged increase in sodium intake
to 270 nimol/day for seven days which causes an increase in blood
pressure in normotensive offspring (mean age 25 3 years) of
hypertensive parents does not raise the blood pressure in offspring
of normotensive parents [33]. The effect on the blood pressure of
a person's customary salt intake, as measured by 24-hour urinary
sodium excretion, has also been studied in normotensive offspring
of two hypertensive parents, one hypertensive parent and two
normotensive parents (mean ages of 21, 22 and 23 years).
Twenty-four-hour urinary sodium excretion was similar in the
three groups, but while there was a positive association between
urinary sodium excretion and systolic blood pressure in the
offspring of hypertensive parents, no such association was appar-
ent in the offspring of two normotensive parents [34].
These observations and experiments have led to the hypothesis
that in essential hypertension and hypertensive strains of rats
there is one initiating factor, a genetically abnormal kidney, the
functional expression of which is a restricted ability to excrete
sodium. This sustained restraint on sodium excretion causes a
tendency to volume expansion which stimulates a sustained
activity of compensatory volume adjusting mechanisms. It is the
persistent presence of these compensatory mechanisms that
causes a rise in blood pressure which helps overcome the kidney's
unwillingness to excrete sodium. The notion that hypertension is
a compensatory phenomenon is an elaboration of an idea first put
forward in 1871 by Traube to explain the rise in blood pressure
that occurs when the kidneys are grossly diseased. He suggested
that ". . . the shrinking of the renal parenchyma will. . . act by
decreasing the amount of liquid which is removed from the
arterial system by urinary excretion. As a result. . . the mean
pressure of the arterial system must increase" [35]. This antici-
pated by about 100 years the application of this proposal to the
urinary excretion of sodium in essential hypertension when Borst
and Borst de Gues suggested that in spite of the macro- and
microscopically normal appearance of the kidney [36, 37] the
arterial pressure had to rise in order to correct the kidney's ".
unwillingness to excrete sodium. Thus a seemingly normal sodium
output is maintained at the expense of the hypertension" [26], a
suggestion subsequently developed by Guyton [38].
The hypothesis proposed is most strongly supported by the
evidence provided by the hypertensive strains of rat. In essential
hypertension there is the tenuous nature, by necessity, of the cross
transplantation evidence and the reasonable objection that the
abnormalities of sodium excretion observed in the normotensive
offspring of hypertensive parents do not necessarily indicate that
they are due to a primary abnormality of the kidney. Nevertheless,
the proposal that in essential hypertension, the kidney as an organ
is genetically flawed in relation to sodium excretion is endorsed by
the finding that it shares a variety of renal abnormalities with the
kidneys of hypertensive strains of rat, and that most of these
abnormalities are potentially capable of impairing sodium excre-
tion. The following review draws attention to recognized inherited
primary renal abnormalities in essential hypertension and hyper-
tensive strains of rat.
The renal circulation: The relation between renal arterial
perfusion pressure and urinary sodium excretion
Essential hypertension
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Investigations of renal hemodynamics in normotensive children
of hypertensive parents have yielded inconsistent results, but the
majority suggest that increased renal vascular resistance precedes
the development of systemic hypertension. Hollenberg, Williams
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and Adams [39] and Uneda et a! [40] reported that renal vascular
resistance was increased despite renal plasma flow and the
glomerular filtration rate being within normal limits. Increased
renal vascular resistance with a lower renal blood flow and an
increased filtration fraction has also been found in offspring of two
hypertensive parents [41]. Interestingly, intermediate values were
reported in subjects with one hypertensive and one normotensive
parent. In contrast, Bianchi et al [42] found renal blood flow and
glomerular filtration rate to be elevated. These conflicting results
may reflect heterogeneity of the hypertensive parents studied, a
degree of hypertension in the 'prehypertensive' subjects or possi-
bly, methodological problems in the determination of plasma flow
and glomerular filtration rate. Bianchi et al [42] used a "plasma-
only" method to measure renal blood flow and glomerular
filtration rate, van Hooft et al [41] found that the reduction in
renal blood flow in the children of hypertensive parents was
greater when renal hemodynamics were measured by a plasma
and urine collection method, than with plasma alone. An increase
in renal vascular tone is consistent with the exaggerated renal
vasodilator response to the calcium antagonist, diltiazem, which
occurs in normotensive first degree relatives of patients with
essential hypertension [43]. Finally, in a post mortem study of
young people (15 to 54 years) from five different populations, the
degree of renal arterial narrowing (measured as intimal thickness
as a percentage of outer vessel diameter) correlated with the
incidence of blood pressure elevation in these ethnic groups.
However, the age-matched blood pressure data came from reports
of cross sectional surveys in these five populations and was not
data from the deceased [44].
The question remains as to the mechanism responsible for the
increased renal vascular tone. The only tenuous evidence is
derived from a study by Schwartzman et al [45]. The authors
investigated the cytochrome P-450 pathway of arachidonic acid
metabolism in renal cortical microsomes obtained from five
persons aged 22 to 42 years a few hours after death in car
accidents and from another person aged 42 years who died of a
cerebral hemorrhage possibly due to essential hypertension. Ep-
oxygenase and oilw-1 hydroxylase activity (which are responsible
for the generation of vasoactive metabolites) were highest in the
microsomes of the person who had died of a cerebral hemorrhage.
Inherited strains of hypertension
Spontaneously hypertensive rat (SHR)
Morphological changes in cortical vessels of SHR. Allerent arte-
rioles are already smaller in the prehypertensive 3- to 4-week-old
SHR [46] than in the WKY rat. They are also smaller in the
6-week-old SHR [71 and in the unilateral nephrectomized
7-week-old SHR [48]. The most significant finding was the
negative correlation between lumen diameter at seven weeks and
the mean blood pressure at 23 weeks in the uninephrectomized
SHR. Morphological measurements demonstrated that the lumi-
nal narrowing was due to hypoplasia as opposed to an increase in
vasoconstrictor tone [49] or medial hypertrophy. Hsu, Slavicek
and Kurtz, however, noted no difference in afferent arteriolar
diameter in SHR at four weeks, although the arteriolar diameter
was reduced at eight weeks [501.
Renal hemodynamics in the SHR. Renal blood flow and glomer-
ular filtration rate in the spontaneously hypertensive rat (SHR) is
reduced before the rise in blood pressure [51]. As the blood
pressure rises in the immature animal, a negative correlation
develops between mean arterial pressure and both renal blood
flow and glomerular filtration rate (as described in essential
hypertension [411) that is absent once hypertension is established
[51, 52]. Also, the kidney of the immature prehypertensive SHR
demonstrates blunted pressure-natriuresis which worsens with
maturity, so that by the age of 10 to 20 weeks an increase in
perfusion pressure of 54 mm Hg gives rise to only a fourfold rise
in urine flow and sodium excretion compared to a ninefold
increase in controls [531. The possibility that this blunted pres-
sure-natriuretic relationship is due to an increase in renal vascular
tone is discussed below.
Medullary hemodynamics in the SHR are abnormal [541.
Roman and Kaldunski [55] used Doppler laser flowmetry to
measure whole kidney cortical and papillary flow in three cohorts
of SHR and WKY rats at 3 to 5 weeks, 6 to 9 weeks and at 12 to
16 weeks. Cortical and whole kidney blood flows were similar
between both groups of rats over a range of perfusion pressures,
whereas SHR papillary blood flow was consistently less. Roman
and Kaldunski [55] proposed that the increased medullary vascu-
lar tone prevents the normal increase in renal interstitial pressure
upon which the mechanism of pressure-natriuresis depends and
that the decreased papillary blood flow (30% less than control) in
the 6- to 9-week-old cohort would enhance sodium reabsorption,
which at this time usually accompanies the rapid development of
hypertension.
These hemodynamic abnormalities persist after the hyperten-
sion is established. At 9 to 10 weeks the renal interstitial pressure,
measured using a unilateral chronically implanted polyethylene
matrix, shows a blunted response to elevation of perfusion
pressure, presumably due to the poor transference of pressure to
the interstitium [56]. When, however, the renal interstitial pres-
sure is increased by direct injection of 2.5% human albumin into
the interstitium there is, in the 12- to 14-week-old SHR, an
exaggerated natriuretic and diuretic response that suggests not
only that the mechanism for pressure-natriuresis remains intact,
but that it may have become more sensitive [57]. That the
impaired ability to excrete sodium is due to an increase in
medullary vascular tone is further supported by experiments in
which the relationship between sodium excretion, interstitial
pressure, papillary flow and the renal artery perfusion pressure in
the 12- to 16-week-old SHR is raised towards normal by the
administration of vasodilators, such as the calcium antagonist,
nisoldipine [58], and by the infusion of captopril directly into the
renal medullary interstitium [59]. Conversely, papillary vasocon-
striction induced by the long term infusion of L-nitro-arginine
methyl ester (L-NAME), [a nitric oxide synthase (NOS) inhibitor]
into the medulla of the normal rat, which reduces papillary blood
flow by nearly 30%, has no effect on cortical blood flow but causes
a decrease in sodium excretion and thereby a rise in blood
pressure [60].
Disturbance of arachidonic acid metabolism in the SHR kidney
Cyclooxygenase activity. Some indication that abnormalities of
vasoconstrictor metabolites of arachidonic acid are involved in the
SHR kidney is derived from a study in which an injection of
arachidonic acid into the renal arteries of isolated perfused
kidneys induced greater renal vasoconstriction in kidneys from
6-week-old SHR than from WKY rats. By 18 weeks, however, this
differential was lost [61]. The implication that this was due to
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increased activity of prostanoid synthesis has been confirmed by
finding that cyclooxygenase activity in rat renal medullary micro-
somes is increased from 2 to 20 months while degradation is
decreased [62, 63]. The perfusate from an SHR kidney at six
weeks contains more thromboxane B2, the stable metabolite of
the potent vasoconstrictor thromboxane A2, than that of the
WKY perfusate, but this difference is no longer present at 18
weeks. Indeed, some compensation may have occurred as vasodi-
latory prostaglandin-like substances, though similar at six weeks in
the SHR and WKY are increased in the 18-week-old SHR [61].
Furthermore, at 6 to 8 months, if isolated glomeruli are super-
fused with large amounts of arachidonic acid, twice the amount of
PGF2,, PGE2 and thromboxane B2 is synthesized in the SHR
glomeruli than in those of the WKY [64]. Prostaglandin-induced
stimulation of renin release and angiotensin formation may also
be responsible for further vasoconstriction, for Jackson and
Herzer [65] have demonstrated reversal of renal vasoconstriction
by indomethacin in the SHR, but not the WKY, in response to
angiotensin II infusion, the inhibition by indomethacin being
reversible by infusion of PGI2.
Cytochrome P-450 dependent monooxygenase activity. There are
multiple forms of cytochrome P-450 with differing substrate
specificity, positional specificity and stereospecificity. In the pres-
ence of NADPH certain forms of cytochrome P-450 dependent
monooxygenases (epoxygenase, w hydroxylase and w-1 hydroxy-
lase) in the human and rat kidneys metabolise arachidonic acid to
a variety of oxygenated products. Epoxygenase activity leads to
the production of 11,12 epoxyeicosatrienoic acid (11,12-EET),
which can be hydrolysed by epoxide hydrolase to 11,12 dihydroxy-
eicosatrienoic acid (11,12-DHT), while w and ia-i hydroxylase
activity leads to the production of 20 hydroxyeicosatetranoic acid
(20-HETE) and 19 hydroxyeicosatetranoic acid (19-HETE). In
the normal rat a high sodium diet causes a marked increase in
renal microsomal epoxygenase activity with no significant change
in microsomal ia/ia-i oxygenase activity [66]. The w hydroxylation
of arachidonic acid in the kidney is an activity associated with
cytochrome P-450 IV Al gene family [671. Both 8,9-EET and
14,15-EET have been detected in human urine [68] and 20-HETE
has been found in SHR urine [69]. The EETs and 19- and
20-HETEs have a wide spectrum of biological activity including
vasodilation, vasoconstriction and inhibition and stimulation of
Na,K-ATPase activity [70—72]. Epoxygenase also leads to
production of 5,6-EET that appears to be particularly potent,
causing renal vasoconstriction and reduced glomerular filtration
rate without effect on blood pressure or sodium excretion [73, 741.
No data, however, are available regarding its role in the hyper-
tensive rat.
The observation by Sacerdoti et al [75] of higher levels of both
cytochrome P-450 and its products in microsomal fractions from
5- to 13-week-old SHR kidneys compared with WKY provoked
them to a further study to determine the effect of renal cyto-
chrome P-450 depletion on the blood pressure of the SHR.
Treatment with tin (SnC12) for four days caused a reduction of the
blood pressure of 7-week-old SHR that was maintained for at
least seven weeks and associated with a natriuresis and reduction
in the renal content of cytochrome P-450 and its arachidonic acid
metabolites. (Tin [76] stimulates renal heme oxygenase produc-
tion and so reduces the availability of heme for the formation of
other hemoproteins including cytochrome P-450 monooxygen-
ases.) Tin, however, did not affect the blood pressure of either
20-week-old SHR or WKY rats. Later the same investigators [771
administered tin chronically to SHR from the age of 5 to 13 weeks
and found that the development of hypertension was prevented
during treatment and for seven weeks thereafter. Imig et al [46]
further implicated cytochrome P-450 in a study of isolated afferent
and interlobular arteries from the three to four weeks SHR. They
were narrower than those of the WKY and dilated more markedly
in response to inhibitors of cytochrome P-450. A pressor role for
cytochrome P-450 metabolites in the enhanced tone of preglo-
merular vessels is also suggested by the observation that levels of
20-HETE, a vasoconstrictor, are higher in cortical microsomes
from SHR than in those of WKY. Indeed a progressive increase
in 20-HETE, 11,12-EET, 11,12-DHT and 19-HETE has been
documented in SHR renal cortical microsomes from three days
prior to parturition through to nine weeks post partum [78].
Increases in 20-HETE levels being particularly marked (27-fold).
In each case levels of metabolites, excepting 11,12-EET, were
higher in SHR than WKY controls. As anticipated, these changes
correlated with steep rises in the activity of w and w-1 hydroxy-
lases that were significantly higher in SHR. In contrast, epoxyge-
nase activity rose equally steeply in both SHR and WKY rats, but
EET levels were still less in the SHR due to its enhanced
conversion to DHT by epoxide hydrolase. Metabolites of w and
w-1 hydroxylases, particularly 20-HETE and its metabolites, are
potent vasoconstrictors and thus their increased production dur-
ing the early weeks when blood pressure is rising may contribute
to the increased renal vascular tone. Furthermore, the altered
profiles of these metabolites may account for the observed
increase in Na,K-ATPase activity [79] and sodium retention in
young SHR since 19-HETE (increased in the SHR) and 11,12-
EET (reduced in the SHR) stimulate and inhibit Na,K-
ATPase, respectively [721.
Nitric oxide synthase activity in SHR kidney
There is no evidence that increased renal vascular tone in the
young prehypertensive SITIR results from defective nitric oxide
(NO)-mediated vasodilatation. Chen and Sanders [80] were un-
able to reverse hypertension in 6-week-old SHR by the adminis-
tration of L-arginine, and measurement of nitrite-nitrate concen-
trations in the effluent of isolated perfused 16-week-old SHR and
WKY kidneys showed no difference [81].
Dahi salt-sensitive (DSS) rats
In common with the SHR, isolated blood-perfused DSS kidneys
require a higher perfusion pressure than DahI salt resistant (DSR)
kidneys to excrete an equivalent amount of sodium and water [82].
This abnormal pressure-natriuresis relationship is present in vivo
both before and after the rise in pressure [83, 84]. The develop-
ment of hypertension is associated with reduced papillary blood
flow but the relationship between papillary flow, renal perfusion
pressure and renal interstitial pressure appears to be normal in
prehypertensive DSS rats. This suggests that in contrast to the
SHR the abnormal pressure-natriuresis may not be due to the
reduced papillary blood flow [851. Recent evidence [86] may
provide some insight into the underlying defect. The infusion of
2% albumin through implanted renal interstitial catheters in
prehypertensive DSS and DSR rats to increase renal interstitial
pressure led to smaller diuretic and natriurctic responses in the
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DSS than in the DSR rat which suggests reduced renal tubular
sensitivity to increased interstitial pressure.
Disturbance of arachidonic acid metabolism in the DSS kidney
A role for arachidonic acid metaholites in the pathogenesis of
increased renal vascular tone in DSS rats is suggested by evidence
that the renal cortical and medullary concentrations of the
vasodilators PGE2 and PGD2 are significantly lower and that the
concentration of the vasoconstrictor thromboxane B2 is signifi-
cantly higher in the barely hypertensive DSS than in the normo-
tensive DSR [871. In addition, though a high salt intake raises
renal epoxygenase activity in the DSR in a normal manner there
is no such rise in the DSS rat [881, and indeed, in the DSS rat
outer medullary production of 20-HETE and the expression of
the P450-4A enzyme is threefold lower. Although failure of signal
transduction rather than increased medullary vascular tone (as in
the SHR) seems to underly sodium retention in the DSS, there is
some evidence for abnormal vascular reactivity of the renal
arteries. Simchon et a! [89] reported an absence of vasodilation to
atrial natriuretic peptide and nitroprusside and an increased
vasoconstrictor response to norepinephrine and angiotensin II in
renal arteries of the prehypertensive DSS rat. In addition, endo-
thelin-1 caused renal vasoconstriction in the DSS rat but vasodi-
latation in DSR rats.
Nitric oxide synthase activity in the DSS kidney
In contrast to the SHR, dysfunction of the nitric oxide system
has been implicated in DSS rats. Chen and Sanders [801 noted
increased NO production in DSR but not in DSS rat on a high salt
diet. Induction of hypertension in the DSS rat on an 8% NaCI diet
for two weeks could be offset by co-administration of L-arginine,
the nitric oxide synthase substrate, although no controls with
D-arginine (the inactive isomer) were undertaken. These results
support those of Hayakawa et al [81], who found nitrate and
nitrite to be reduced in the effluent of hypertensive DSS kidneys.
Together these studies suggest that one factor responsible for the
development of salt-induced hypertension in the DSS rat is an
inability to increase vasodilatory NO production, perhaps because
L-arginine availability is rate-limiting. In a later study, the protec-
tive effect of L-arginine was prevented by pre-treatment with
dexamethasone, an inhibitor of inducible NO synthase that impli-
cates a defect of this isoform of NO synthase [90].
Summary
Pressure-natriuresis relationships are abnormal in young nor-
motensive offspring of (a) patients with essential hypertension and
(b) rats with hereditary hypertension and could provide one
pathway by which an impaired ability to excrete sodium leads to
hypertension. In the SHR this appears to be the result of
enhanced renal vascular tone, apparently as a result of a distur-
bance of arachidonic acid metabolism, which prevents an increase
in renal perfusion pressure raising the renal interstitial pressure.
In the DSS however, though there is evidence of enhanced renal
vascular tone and vascular reactivity, the impaired pressure
natriuresis is due principally to a defect in the sensitivity of the
renal tubule to diminish sodium reabsorption in response to
changes in interstitial pressure. It is not known whether either of
these two mechanisms underly the abnormal pressure natriuresis
relationship in essential hypertension.
The renin-angiotensin system
There is a possibility that an intrinsic abnormality of the
renin-angiotensin system in the kidney is concerned with the
impaired ability of the kidney to excrete sodium in essential
hypertension and hypertensive strains of rats. Angiotensin II is
directly involved in sodium reabsorption by a direct effect on the
tubules and by its vasoconstricting effect that lowers peritubular
hydrostatic pressure and glomerular filtration rate. There is
widespread expression in the kidney of the genes involved in the
renin-angiotensin system.
Several observations in humans point to a direct relationship
between plasma angiotensinogen and the blood pressure. Jeun-
emaitre et al [91] have studied the relationship of the angio-
tensinogen gene (AGT) in 215 American and French siblings,
each with two or more hypertensive subjects yielding a total of 379
sibling pairs. They obtained evidence of genetic linkage between
the angiotensinogen gene and hypertension, demonstrated an
association between certain molecular variants of AGT at position
235 and 174 and hypertension, and found differences in plasma
concentrations of angiotensinogen among Caucasian hypertensive
subjects with different AGT phenotypes. One of these variants, an
amino acid substitution of threonine for methionine at codoo 235,
was also associated with essential hypertension in a study of 105
Japanese hypertensive subjects and 81 controls [92]. In a third
study in 63 multiplex families in England in which two or more
members had essential hypertension significant linkage was found
between the angiotensinogen gene locus and essential hyperten-
sion, but not to variants at position 235 or 174 [93]. It is significant
that overexpression of the angiotensinogen gene in a transgenic
animal model is associated with hypertension [94].
Three other candidate genes of the renin system have recently
been excluded from participating in essential hypertension. In
cross breeding studies in both the stroke-prone spontaneously
hypertensive rat (SPSHR) and the Dahi salt-sensitive rat, genetic
markers of the ACE gene and closely related markers on chro-
mosome 10 were linked to the inheritance of blood pressure in
genetically segregated F2 rats [95—98]. In 170 adult Caucasians
with a wide range of contrasting genetic pre-disposition to high
blood pressure, however, the ACE gene was not associated with a
genetic pre-disposition to high blood pressure [99], a conclusion
confirmed by Schmidt et a! [100] in both parents (N = 111
parents) who had high and low blood pressures, and their
offspring (N = 75). Restriction fragment length polymorphism of
the renin allele has been identified in the SHR and Dahl
salt-sensitive rat with an increase in renin mRNA in the kidney.
liver, brain, adrenal and heart in the young SHR [101—103]. But
Lindpainter, Takahashi and Ganten [104] failed to show co-
segregation of the renin genotype and arterial blood pressure in
the stroke-prone spontaneously hypertensive rat (SPSHR). Simi-
larly, in human hypertension, Naftilan et a! [1051 and Soubrier et
al [106] have also failed to find a genetic linkage of renin gene
restriction fragment length polymorphism with blood pressure. In
a case control study on the association between 298 hypertensive
subjects with a positive family history and 293 normotensive
controls for mutations of the angiotensin TI-type receptor (AT-i)
gene, Soubrier et a! found no support for a role for the AT-i gene
in human hypertension [106].
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Summaiy
Genetic abnormalities of the renin-angiotensin system are
present in both essential hypertension and hypertensive strains of
rats, but the genes responsible are different.
Dopamine
Dopamine, which regulates tubule sodium transport is a potent
vasodilator and inhibits Na,K-ATPase. Renal production of
dopamine, as measured by urinary dopamine excretion, may
increase in response to sodium loading in both humans [107] and
experimental animals. There are important ethnic variations in
that salt loading increases urinary sodium and dopamine in some
(Caucasians, Thais, Zimbabweans) but not in all (American
Blacks, Ghanaians and Iranians) normotensive groups [108].
Dopamine in essential hypertension
Although basal production of dopamine in essential hyperten-
sion is normal, there is evidence that regulatory processes are
abnormal in that the increase in urinary dopamine in response to
salt loading is attenuated [1091 or reversed [1101. A blunted
response of dopamine to salt loading is present in salt-sensitive
but not salt-resistant hypertensive individuals [111, 112] and also
occurs in the normotensive relatives of hypertensive patients [113,
114] and in ethnic groups, such as the American Blacks, who have
a high incidence of salt-sensitive hypertension [115]. The mea-
surement of plasma levels of L-DOPA in essential hypertension
provides no evidence of substrate deficiency [111, 116] and urinary
measurements of L-DOPA do not suggest that its delivery to the
kidney is defective. Indeed, Gill, Grossman and Goldstein [1111
noted that in salt-sensitive hypertension, there was reduced
dopamine excretion in the face of enhanced urinary levels of
L-DOPA, suggesting that the "fault" might be in the tubular
uptake of L-DOPA or its subsequent decarboxylation by aromatic
amine de-carboxylase (AADC). This conclusion is supported by a
study in which the decarboxylation of exogenous L-DOPA was
noted to be reduced in hypertensive patients [117]. The identifi-
cation of different mRNAs coding for AADC in neural and renal
tissue hints at the existence of a selective renal AADC defect in
essential hypertension [118]. The enhanced natriuretic, diuretic
and hypotensive response of patients with essential hypertension
to exogenous dopamine or fenoldopam, a specific DA1 agonist, is
also consistent with a state of increased receptor activity which
could reflect a deficiency of dopamine [119, 1201.
Dopamine in the SHR
Basal dopaminc production in SHR and WKY rats is similar
hut, in contrast to patients with essential hypertension, the
increment following salt loading is greater in the SHR [121].
Nevertheless, the SHR is unable to eliminate an acute sodium
load as efficiently as the WKY [122] and exhibits a poor natriurctic
response to exogenous L-DOPA, dopamine [123] or a l)A1
agonist [122, 124]. A defect in the SHR's DA1 receptor could
account for this, but there is no evidence to suggest loss of DA1
receptor density or affinity [124, 125]. The DA1 receptor from the
proximal collecting duct of the SHR shows structural homology
with receptors from the WKY rat and the striatum [126], and
there is no evidence of defective binding of dopamine to the DA1
receptor in the proximal collecting duct of the SHR [125]. This
leaves the remote possibility that a post-translocational modifica-
tion, such as glycosylation, of the DA1 receptor occurs or more
probably there is a defect distal to the DA1 receptor [124]. Using
a variety of agonists to stimulate adenyl cyclase, Kinoshita, Sidhu
and Felder [126] showed a specific defect in DA receptor adenyl
cyclase coupling in the proximal collecting duct of the SHR that is
not present in the striatum [127, 128]. This appears to be due to
a genetic defect since it is apparent at three weeks [128], and
co-segregates with the hypertensive phenotype [129]. Consistent
with a defect in signal transduction Chen et al [123] have shown
attenuation of dopamine activation of phospholipase C (PLC) in
cortical slices from the SHR, although basal PLC activity was
significantly higher in SHR than in age-matched WKY. The
presence of defects in both effector pathways of the DA receptor
supports pharmacological evidence of defective receptor/Gs pro-
tein coupling [125, 130, 131]. Failure to generate cAMP may
account for the defective inhibition of the Na-H exchanger by
dopamine in the SHR [132], and failure to activate a phospho-
lipase C coupled protein kinase C pathway may account for the
defective inhibition of Na+,K*ATPase by dopamine in the SHR
proximal collecting duct [133].
Dopamine in the Dahi salt-sensitive rat
Salt loading increases L-DOPA excretion to the same extent in
Dahl salt-sensitive (DSS), Dahl salt-resistant (DSR) and Sprague-
Dawley rats [134, 135], and in common with the SHR both
varieties of Dahl rat produce more dopamine than the Sprague-
Dawley rats for a given amount of L-DOPA delivery to the kidney
[135]. In both DSS and DSR rats, however, there is a blunted
natriuretic response to exogenous dopamine compared with the
Sprague-Dawley rat [135] that is apparent even in the prehyper-
tensive phase of the DSS [136]. As with the SHR, there is evidence
of defective coupling between the DA1 receptor and adenyl
cyclase [136, 137] in the DSS, but strangely, not in the DSR rat. It
has been suggested that this anomaly may be due to reduced DA1
receptor expression [136]. Consistent with a defect affecting either
the receptor or subsequent receptor signal transduction, neither a
high salt diet [138] nor dopamine [136] inhibits Na,K-ATPase
activity in segments of proximal tubule and thick ascending limb
of the DSS rat.
Summary
In all forms of hereditary hypertension studied in human and
the rat there is a defect in the renal dopamine pathway which
could contribute to the kidney's impaired ability to excrete
sodium. The elements of the pathways which are abnormal in the
various models of hypertension, however, are different.
Urinary kallikrein
Most filtered kallikrein is destroyed in the proximal tubule and
therefore the origin of urinary kallikrein is predominantly from
the distal tubule where it probably acts on filtered kininogens in
the tubule fluid to release kinins [139]. The cummulative evidence
suggests that bradykinin's physiological role is to increase sodium
excretion both by its vasodilatory effect [1401 and by a direct effect
on the tubule [141, 1421. Kallikrein, which is a protease, hydrol-
yses amiloride-sensitive sodium channels, thus diminishing the
rate of entry of sodium into the cell [143]. If this takes place in the
apical membranes of the distal tubules it may be an additional
mechanism whereby kallikrcin increases urinary sodium excre-
tion. It seems probable, therefore, that a reduction in kallikrcin
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formation would tend to diminish sodium excretion. In normal
humans and animals a decrease in sodium intake raises and an
increase lowers urinary kallikrein excretion [144, 145].
Urinary kallikrein excretion is reduced in essential hypertension
[146], and in normotensive children of hypertensive parents [140],
and furthermore normal individuals who excrete more kallikrein
are significantly less likely to have one or two hypertensive parents
[147]. Urinary kallikrein excretion is also less in the SHR and in
the Dahi salt-sensitive rat [148]. A role for kallikrein in the SHR
has been implied by the observation that restriction fragment
length polymorphism marking the kallikrein gene family co-
segregates with the blood pressure in cross bred strains of the
SHR and the normotensive Brown Norway rat [149]. In renal
cross transplant experiments between DSS rats and DSR rats
Churchill et al [1501 have demonstrated that urinary kallikrein
excretion closely follows the genotype of the kidney rather than
that of the rat, thus the low urinary excretion of the DSS rat is a
genetically determined difference.
Summary
These findings suggest that the diminished excretion of kal-
likrein in essential hypertension and in hypertensive strains of rat,
which begins before the blood pressure has started to rise and
which, in the rat, appears to be due to a genetic fault, may impair
sodium excretion and be another cause for the kidney's impaired
ability to excrete sodium.
Tubuloglomerular feedback
An increase in the glomerular filtration rate increases the rate
of delivery of tubular fluid to the macula densa, the cells of which
then signal the afferent arteriole to constrict. In turn this reduces
the filtration rate and the delivery of tubular fluid to the macula
densa, and reduces urinary sodium excretion [151]. In the normal
animal the sensitivity and reactivity of this tubuloglomerular
feedback increases when there is a need to conserve sodium, as in
hemorrhage [152] and dehydration [1531, and diminishes when
there is a prolonged need to increase sodium excretion, as in
chronic salt loading [154, 155] and DOCA administration [156,
1571.
In the 6-week-old SHR [158, 159] when there is most evidence
of sodium retention and the blood pressure is beginning to rise,
tubuloglomerular feedback activity is increased despite the rise in
blood pressure. This paradoxical increase that should enhance
sodium reabsorption is independent of changes in blood pressure,
since it persists even if renal perfusion pressure is stabilized by
aortic constriction and returns to normal at 12 weeks of age, by
which time the arterial pressure is considerably raised. Con-
versely, if the SHR is chronically salt loaded the resultant fall in
tubuloglomerular feedback is less than in the salt-loaded WKY
rat. By measuring tubuloglomerular feedback activity when per-
fusing the tubule with harvested tubular fluid from SHR and
control rats, Ushiogi, Takabatake and Häberle [160] have dem-
onstrated that the increase in tubuloglomerular feedback activity
in the SHR is due to the defective activation of a feedback
inhibitory substance in the tubule fluid.
The situation is similar in the Milan hypertensive strain (MHS)
[161]. At 3.5 to 5 weeks when the MHS rat is in a state of slight
volume expansion, tubuloglomerular feedback activity is appro-
priately absent. Two weeks later, however, when the blood
pressure has started to rise, tubuloglomerular feedback increases
inappropriately to supranormal levels, so diminishing the kidney's
ability to excrete sodium.
Renal tubule sodium transporters
Multiple abnormalities of renal tubule sodium transporters
have been identified which could impair the kidney's ability to
excrete sodium.
Na,K-ATPase
Na,K-ATPase, which is localized on the basolateral mem-
brane of the tubular cells, is fundamental to the reabsorption of
sodium throughout the nephron and an increase in activity should
lead to an increase in sodium reabsorption. Indeed, in 5- and
8-week-old SHR, Na,KtATPase activity is significantly higher
in micro-dissected proximal tubules but significantly lower in the
thick ascending limb of the ioop of Henle than in the WKY rat.
This difference is no longer present at 20 weeks [162]. There is
also evidence for a defect in the signal transduction pathway
involving Na,K-ATPase activation. Gurich and Beach have
demonstrated an abnormality in G-protein control of Na,K-
ATPase in suspensions of renal proximal tubules in the SHR and
suggest that this could increase sodium reabsorption [130].
In addition a significant mutation of a1 Na,K-ATPase, the
only isoform present in the kidney, has been identified in Dahl salt
sensitive hypertensive male rats in the form of a leucine substitu-
tion for glycine leading to a 3.5:1 sodium:potassium transport
ratio instead of the normal 2:1 ratio found in the normotensive
salt-resistant rat [163, 164]. This change would lead to an excess of
sodium ions reabsorbed by the tubules for every potassium ion
transported.
There is a suggestion that membrane abnormalities, such as the
increase in Na,K-ATPase exchange in the Milan hypertensive
rat, may be related to an abnormality of the adducin gene. The
membrane-skeleton protein adducin is involved in the assembly of
actin and mactin and various actin binding proteins, such as
ankysin, which couple to a variety of transmembrane proteins
including most ion transport molecules. One such coupling is to
the a subunit of Na,K-ATPase in epithelial cells [165]. Addu-
cm was originally chosen for genetic studies in the Milan hyper-
tensive strain (MHS) because it was the only membrane skeletal
protein eliciting an immunological response in cross immuniza-
tion experiments with the Milan normotensive strain (MNS).
Adducin is an aj3 heterodimer that promotes the organization of
a spectinactin lattice. Bianchi et al [166] have found a mutation in
each of the two genes which code for adducin. In the a subunit
there is a tyrosine (MHS) to phenylalanine (MNS) substitution
and in the 13 subunit there is an arginine (MHS) to glutamine
substitution (MNS). Furthermore, it has recently been found that
normal rat kidney epithelial cells transfected with mutated rat
adducin cDNA differentially modulates actin assembly (G. Bian-
chi, personal communication). The mutant cells have an increased
surface expression of Na,K -ATPase and a raised Na,K-
ATPase activity at Vm• There is a high degree (94%) of amino
acid homology between rat and human adducin, and many of the
renal cell membrane ion transport alterations of the MHS rat are
shared by a subset of patients with essential hypertension: 190
hypertensive patients and 120 controls were genotyped by four
markers surrounding the adducin locus [167]. The distance of the
marker from the adducin locus was found to be related to the
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diastolic pressure, which supports the hypothesis that the adducin
locus is also involved in essential hypertension.
Sodium hydrogen anhiporter
The activity of the Na-H exchanger is raised in erythrocytes
and lymphocytes of about 50% of patients with essential hyper-
tension and in the SHR [168—173]. Renal brush border membrane
vesicles from young pre-hypertensive MHS rats [1741 and SHR
[1751 demonstrate an increased sodium uptake via the Na-H
exchange. It is also relevant that transgenic mice overexpressing
the Na-H exchanger, including the renal tubules, become
transiently hypertensive during salt loading [176]. Such mutant
mice also have a reduced fractional sodium excretion, plasma
renin activity and aldosterone. Four isoforms of the sodium
hydrogen exchange have been cloned. The NHE-1 isoform is
amiloride-sensitive and expressed in all cell types; in polarized
cells it lies in the basolateral membrane. NHE-2, NHE-3 and
NHE-4 isoforms are predominantly in epithelial cells in which
they appear to be involved in the transepithelial transport of
sodium. The brush border contains the NHE-3 isoform.
At one time it was not clear whether the increased Na-H
exchange activity in essential hypertension and hypertensive
strains of rats was due to some systemic metabolic disturbance, a
primary genetic defect or altered intracellular regulation. A mild
metabolic acidosis has been reported in essential hypertension
[177], the SHR, the Milan hypertensive rat and the SPSHR [178].
Furthermore, long-term acidosis appears to induce an increase in
Na-H exchange activity in the rat kidney [179] and in human
lymphocytes [1801. It has also been shown that changes in sodium
intake from 20 to 300 mmol/day can increase NHE activity in
lymphocytes from normotensive volunteers by approximately
35%. More moderate alterations in sodium intake, however, had
no effect [181].
The cause of the increased NHE activity in essential hyperten-
sion has been considerably clarified by Siffert and DUsing [182],
who have immortalized lymphoblasts from normotensive subjects
and patients with hypertension with low and high NHE activity.
They have found that the enhanced NHE activity persists in the
immortalized cells from hypertensive patients, which therefore
excludes extracellular factors such as systemic acidosis and salt
intake. Several lines of evidence suggest that the abnormality of
NHE involves the NHE-1 isoform of antiporters and that it is not
overexpressed. Neither does it appear to be mutated, for Lipton et
al's genetic studies in essential hypertension [183] failed to
demonstrate linkage of the Na-H antiporter locus with hyper-
tension, and Rosskopf et al [1841, having sequenced the complete
eDNA, encoding for NHE-1 from immortalized hypertensive and
normotensive cell lines with low and enhanced NHE activity, did
not find any sequence changes. Siffert and Dusing conclude that
the enhanced NHE activity in primary hypertension is best
explained by altered intracellular regulation secondary to some
other intracellular disturbance. There is evidence that NHE
activity is regulated by a Ca2-calmodulin mechanism and by
certain specific G-protein a subunits. Although the isoform was
not identified Ng et al [1851, using lymphocytes from patients with
essential hypertension, have found that the increased Na-H
activity is associated with increased phosphorylation.
Summary
NHE activity is increased in hereditary hypertension. If abnor-
mal regulation of this antiporter, as observed in immortalized
lymphoblasts from patients with essential hypertension, is gener-
alized and underlies the increase in Na-H activity in the renal
brush border vesicles from hypertensive strains of rats, it would
follow that the consequential increase in sodium reabsorption is
due to a primary defect in the renal cells and it could be one of the
intrinsic renal factors that contribute to the kidney's unwillingness
to excrete sodium, which results in hypertension.
Sodium potassium co-transport
Theoretically an increase in renal Na-K co-transport could
impair the kidney's capacity to excrete sodium. In the kidney
Na-K co-transport is restricted to the luminal surface of the
cells of the thick ascending limb of the loop of Henle (the site of
action of frusemide and bumetamide) and plays a fundamental
role in counter current multiplication and the elaboration of a
hypertonic interstitium [186]. Na4 -K co-transport of red cells
from patients with essential hypertension [187] and the SHR is
reduced [188], but in the Milan hypertensive rat red cell Na-K4
co-transport is greater than in the normotensive control rat both
in the pre-hypertensive and adult stages [189]. This difference in
the MHS rat is genetically related to hypertension as shown by
bone marrow transplantation [190] and in the red cells of F2-
hybrids obtained by crossing F1 (MHS x MNS) hybrids [191]. The
Na-K co-transport of MHS thick ascending limb vesicles is also
significantly greater than in the normotensive controls [1921. In
the SHR, in contrast to the MHS, the thick ascending limb vesicles
appear to have a reduced Na-K co-transport, in line with the
red cells (Karlish S.J.D. and Garay R., unpublished data quoted in
[192]).
Atrial natriuretic peptide (ANP) receptor
In essential hypertension ANP binding sites (platelets) are
normal [193] and bolus administration of ANP induces an exag-
gerated increase in sodium excretion [194]. In the kidney of the
adult SHR the receptor is usually more densely expressed [195]
than in WKY kidneys, and in both young pre-hypertensive and
adult SHR each receptor produces cyclic GMP at a higher rate
[1961. In contrast, in the DSS hypertensive rat the guanyl cyclase
ANP receptor (GCA) gene co-segregates with the blood pressure
[97]. This suggests that in the DSS the hyporesponsiveness of the
kidneys to ANP [197], which could impair the kidney's ability to
excrete sodium, may be due to a genetic defect of the renal GCA
receptor. However, the possibility that it can also be secondary to
the hypertension is raised by the recent observation that there is
GCA down-regulation and possible defects in cGMP signal
transduction in the one kidney, one clip hypertensive dog [198].
S3, S2 and SA DNA clones
Inherited rat strains of hypertension
Recognizing that the renal cross transplantation experiments
suggest that the primary defect that causes the blood pressure to
rise is situated in the kidney, and acknowledging that renal
function must be altered as a prerequisite for the maintenance of
all forms of hypertension [199], Iwai and Inagami [200] have
explored the possibility that certain genes might be preferentially
expressed in the SHR and WKY kidneys. They isolated three
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complimentary DNA clones (designated S3, S2 and SA), that
hybridize to the mRNA species, differentially expressed between
the kidney of the SHR and the WKY rat. Sequence analysis of S3
revealed that it encodes rat cytochrome P450 IV A2 mRNA, the
specific substrate for which is not known. The expression of the S3
mRNA in the SHR kidney at 10 days of age is already greater than
in the WKY kidney and it is four times greater at 28 days, but at
sixteen weeks there is no difference. The expression of the S3
gene, however, appears to be influenced by the dietary intake of
sodium in that in the Sprague Dawley rat it rises 2.5 times after a
low NaC1 diet for two weeks.
No homologous nucleotide for the 2 clone has been found. At
10 days the S2 clone was not detected in the kidney of the SHR or
the WKY rat, and at 28 days, while 2 mRNA was still almost
undetectable in the kidneys of the WKY rat, it was clearly
detected in the SHR. Expression of the S2mRNA in the kidney
was not modulated by a low NaC1 diet.
From the age of four weeks there is 10 times more SAmRNA
expressed in the kidneys (proximal tubule) of the SHR than in the
kidneys of the WKY rat in which its expression remains persis-
tently low [201]. The expression of the A gene in the SHR kidney
was not influenced by a low NaC1 diet while it was slightly
increased (x 1.5) by Captopril. Small amounts of 5A gene
expression is detectable in the brain. As in the kidney, it is
markedly lower in the brain of the SHR than in that of the WKY
brain [202, 203]. Iwai et al have analyzed the genotype of the SA
gene of F2 rats obtained by cross breeding SHR and WKY and
found that the blood pressure of the F2 rats inheriting two SHR
alleles of the 5A gene is significantly higher than that of the F2 rats
inheriting two WKY alleles. Similar results have been obtained in
the DSS rat [202]. In an F2 population prepared from SHR and
the Lewis rat, a correlation between the 5A gene and the blood
pressure was only observed in the female rats [204]. This makes it
highly probable that the A gene in the kidney or the brain is
indirectly responsible for the hypertension in the SHR and the
DSS rat. The limited tissue distribution of expression of the gene
and its temporal pattern re-enforces this conclusion. The strong
co-segregation of the 5A gene with an increase in blood pressure
in F2 rats has been confirmed by Samnani et a! [203] and by
Lindpainter et al [205]. Samnani also pointed out that though the
expression of the 5A gene is raised in the SHR by the sixth week,
the blood pressure in the F2 rat does not rise until the 16th week.
Essential hypertension
Studies in essential hypertension exhibit geographical variabil-
ity. Iwai et al [206] have reported a significant association of the
5A genotype with hypertension in three groups of Japanese. On
the other hand Nabika et a! [207] found that in a large sample of
hypertensive patients, normotensive controls and multiplex sib-
lings in France, association and linkage studies with markers of
the SA gene and other microsatellites in close proximity to the 5A
gene reveals no evidence to suggest that the gene is involved in
human hypertension. Similarly, Harrap et al [2081 in West Scot-
land have found that the frequency of the 5A gene allele is not
significantly different between normotensive subjects with high
parental blood pressures and those with a low parental blood
pressure. Nor does GFR, renal blood flow, renal vascular resis-
tance and the concentration of the circulating components of the
renin angiotensin system differ according to SA genotype [208].
Summary
The 5A gene, which is preferentially expressed in the SHR and
DSS rat kidney, the product of which is not known may play an
important role in the kidney's contribution to the hypertensive
process in these two hypertensive strains of rat, but evidence to
support a similar role in essential hypertension is weak. It is not
known whether the 5A gene product controls sodium excretion.
Renal developmental abnormalities and sodium excretion
The human kidney
Age. In normal humans the kidney's capacity to excrete sodium
decreases with age [209], the result being that a smaller acute
increase in salt intake induces a rise in arterial pressure [210].
There is an accelerating fall in GFR with age which begins around
the age of 30 years [211, 212], so that at the age of 80 years the
mean fall in GFR is about 40%. But individual variations vary
widely and in one longitudinal study of 254 subjects, who were
followed serially for eight or more years, one third had no fall in
GFR [212]. The overall deterioration in GFR is more marked in
blacks [213] in whom creatinine clearance at age 70 years is 20%
lower than in whites. It is accompanied by a decline in the number
of functioning nephrons and is associated with a progressive
development of glomerulosclerosis [214, 215]. As there is gener-
ally no decline in salt consumption with age, sodium balance is
achieved in part by raising the fractional excretion of sodium, and
this is associated with an increase in the circulating concentration
of ANP [2161 and a fall in plasma renin and aldosterone [217].
Senescence is normal and therefore the waning capacity of the
ageing and shrinking kidney to manipulate sodium excretion [208]
is not a primary renal abnormality, the subject of this review.
Nevertheless, it is probable that the gradual rise in blood pressure
that occurs with age in all populations on a diet that contains more
than 60 mmol of sodium per day [218] is due to these involutional
changes superimposed on the primary renal abnormalities de-
scribed above.
Intrauterine growth. It is possible that in some patients with
essential hypertension the rise in pressure is due to impaired
intrauterine growth of the fetal kidney. Sixty percent of the
nephron population develops in the third trimester [219], and
severe intrauterine growth retardation in human fetuses has been
shown to exert a profound effect on renal development [220].
These facts are probably relevant to the finding, based on
retrospective analysis of hospital records, that at all ages beyond
infancy, people with lower birthweights have a higher blood
pressure [221, 222], a relationship that becomes greater with age.
The observation, however, of a weak inverse relationship between
maternal blood pressure and infant birthweight complicates this
analysis [223], since it suggests that impaired growth may reflect
an inherited tendency to higher blood pressure.
Animal kidneys
In the normal rat GFR begins to decrease at three months with
a mean fall of about 30% at 24 months [224]. A relationship
between fetal development and hypertension can be demon-
strated in animals. Ligation of one uterine artery in the guinea pig
[225] retards intrauterine growth in the fetuses on the ligated side
while the others, on the normal side, grow normally. Later, the
low birth weight animals develop a higher blood pressure. In rats,
maternal low protein diets, maintained throughout pregnancy,
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impair renal function of the fetus [226], and at nine weeks lead to
an increase in its blood pressure [2271.
The number and diameter of glomerular capillary fenestrae of
the 6-week-old SHR rat are significantly smaller than in the WKY
rat, and in addition the cytoplasmic ridges that course across the
surface of the capillary endothelium are increased in number
[228]. These changes may explain the SHR's lower glomerular
capillary ultrafiltration coefficient [491. The weight of the pre-
hypertensive 64-day-old MHS rat kidney is lower than the MNS
rat [229] and it also contains fewer glomeruli, but this difference
between the two strains is not significant [230].
Summary
The ability to excrete sodium decreases with age. In both
humans and experimental animals intrauterine growth retardation
may predispose to hypertension in later life; whether this is in
itself sufficient to lead to hypertension or whether it only com-
pounds the effects of other hereditary renal abnormalities is
unclear.
Discussion
The renal functional abnormalities described, with the excep-
tion of the SA gene, the product of which is not known, are
capable of interfering with urinary excretion of sodium. They are
not secondary to hypertension for they are present in young
normotensive individuals and animals and as they appear to be
inherited it is probable that they are operative from birth. This
implies that sodium balance, during the prehypertensive phase, is
maintained by a variety of compensatory mechanisms such as the
observed lower plasma renin and aldosterone in normotensive
children of hypertensive parents [29, 42]. It is just possible,
therefore, that some of the renal abnormalities which have been
described and which appear to be primary, because they are
present before the blood pressure rises, are nevertheless second-
ary in that they are due to those primary renal defects that do
indeed impair the ability of the kidney to excrete sodium.
Many of the renal functional abnormalities in the various forms
of hereditary hypertension are the same, for instance there are
defects of dopamine and renin-angiotensin metabolism that could
impair urinary sodium excretion, in essential hypertension, the
SHR and the DSS, but the molecular disturbance and thus the
genetic fault that gives rise to them may not be identical. It is
interesting that though patients with essential hypertension share
several functional abnormalities with hypertensive strains of rats,
the precise nature of the few genetic disturbances that have been
detected so far (with the possible exception of the adducin gene)
are different. Functional abnormalities vary from reduced agonist
production to abnormal receptors and dysfunctional signal trans-
duction pathways. Differences in the intracellular mechanism and
the genetic fault responsible for a functional abnormality may also
be evident between hypertensive strains of rat. Furthermore, it is
clear that within a particular model of hypertension an abnormal-
ity may affect only some of the hypertensive population for
instance the increase in Na-H4 exchange activity in essential
hypertension.
The various functional abnormalities described in the kidney
may also be present in other tissues and may contribute to the
phenotypic heterogeneity of hereditary hypertension. Neverthe-
less, whatever changes these may induce in nervous or vascular
tissue, such as increased proliferation, they cannot initiate the rise
in blood pressure, for the blood pressure of a bilaterally nephrec-
tomized hypertensive strain rat does not rise in the presence of a
normal kidney. Experiments with isolated cells will reveal what
genetic abnormalities exist in hypertension. But as the significance
of such abnormalities in the causation of the hypertension appears
to depend on their expression in the kidney, the definition of
which of these abnormalities causes the blood pressure to rise will
have to be explored by performing renal cross transplantation
experiments between normal animals and mutant animals in
which hypertension has been caused by a single genetic manipu-
lation that is widely expressed, for instance of the NHE or
angiotensinogen genes.
Abnormal sodium handling by the kidney underlies the funda-
mental observation that following experimental renal cross trans-
plantation in hypertensive strains of rats, hypertension follows the
kidney and that therefore the primary genetic lesions that stimu-
late the mechanisms which eventually cause the blood pressure to
rise reside in the kidney. The finding that many of the renal
functional abnormalities in the normotensive offspring of patients
with hypertension are the same as in the prehypertensive hyper-
tensive strains of rats, though their genetic origin may be different,
supports the data from therapeutic renal transplantation in hu-
mans and strengthens the proposal that essential hypertension is
also due primarily to an abnormal kidney which has an unwilling-
ness to excrete sodium. In other words, these observations suggest
that essential hypertension and the various forms of hereditary
hypertension in rats are polygenic renal diseases and that if their
origin is to be compared to a mosaic [231] then all the pieces,
though they may be genetically different between and within the
various models of inherited hypertension, would appear to reside
in the kidney where they impair sodium excretion.
In conclusion, several primary renal abnormalities are impli-
cated in the pathogenesis of hereditary hypertension which are
potentially capable of impairing sodium excretion. It is proposed
that their diversity and number, and the particular combination
present, are responsible for the heterogeneity of this form of
hypertension.
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